ATE307132T1 - Purin derivate als a2b adenosin rezeptor antagonisten - Google Patents

Purin derivate als a2b adenosin rezeptor antagonisten

Info

Publication number
ATE307132T1
ATE307132T1 AT02749704T AT02749704T ATE307132T1 AT E307132 T1 ATE307132 T1 AT E307132T1 AT 02749704 T AT02749704 T AT 02749704T AT 02749704 T AT02749704 T AT 02749704T AT E307132 T1 ATE307132 T1 AT E307132T1
Authority
AT
Austria
Prior art keywords
optionally substituted
receptor antagonists
adenosine receptor
purine derivatives
sup
Prior art date
Application number
AT02749704T
Other languages
English (en)
Inventor
Venkata Palle
Vaibhav Varkhedkar
Jeff A Zablocki
Dengming Xiao
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE307132T1 publication Critical patent/ATE307132T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT02749704T 2001-06-29 2002-06-27 Purin derivate als a2b adenosin rezeptor antagonisten ATE307132T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30220801P 2001-06-29 2001-06-29
PCT/US2002/020631 WO2003002566A1 (en) 2001-06-29 2002-06-27 Purine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
ATE307132T1 true ATE307132T1 (de) 2005-11-15

Family

ID=23166757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749704T ATE307132T1 (de) 2001-06-29 2002-06-27 Purin derivate als a2b adenosin rezeptor antagonisten

Country Status (10)

Country Link
US (2) US6770651B2 (de)
EP (1) EP1401837B1 (de)
JP (1) JP4335000B2 (de)
KR (2) KR100883292B1 (de)
AT (1) ATE307132T1 (de)
CA (1) CA2451244C (de)
DE (1) DE60206756T2 (de)
DK (1) DK1401837T3 (de)
ES (1) ES2247356T3 (de)
WO (1) WO2003002566A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
NL1023355C2 (nl) * 2003-05-07 2004-11-09 Oce Tech Bv Hot melt inkt omvattend een mengsel van kleurstoffen.
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2533402A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CA2620182A1 (en) 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
JP5474354B2 (ja) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド 医薬化合物
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
EP2510946B1 (de) 2007-02-07 2015-08-05 The Regents of The University of California Konjugate synthetischer TLR-Agonisten und Verwendung dafür
JP2011500716A (ja) * 2007-10-16 2011-01-06 ギリアード・パロ・アルト・インコーポレイテッド A3アデノシン受容体アンタゴニスト
WO2009099650A2 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
JP5460690B2 (ja) 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
EP2306838A4 (de) * 2008-07-16 2011-12-14 King Pharmaceuticals Res & Dev Verfahren zur behandlung von atherosklerose
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
SI2408775T1 (sl) * 2009-03-20 2015-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila
EP2499142B1 (de) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituierte kondensierte pyrimidinverbindungen, ihre herstellung und ihre verwendung
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 a2b 아데노신 수용체 길항제의 용도
EP2616470B1 (de) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purinverbindungen als prodrugs von a2b-adenosinrezeptorantagonisten, ihr verfahren und medizinische anwendung
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
TWI746545B (zh) * 2016-04-26 2021-11-21 日商大日本住友製藥股份有限公司 經取代嘌呤衍生物
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2020181050A1 (en) 2019-03-05 2020-09-10 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
BR0013673A (pt) * 1999-08-31 2002-05-28 Univ Vanderbilt Antagonistas seletivos de receptores de adenosina a2b
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists

Also Published As

Publication number Publication date
US20040209899A1 (en) 2004-10-21
JP4335000B2 (ja) 2009-09-30
KR100897219B1 (ko) 2009-05-14
ES2247356T3 (es) 2006-03-01
EP1401837B1 (de) 2005-10-19
JP2004536102A (ja) 2004-12-02
HK1064096A1 (en) 2005-01-21
EP1401837A1 (de) 2004-03-31
KR20080081208A (ko) 2008-09-08
DE60206756D1 (de) 2006-03-02
KR20040023634A (ko) 2004-03-18
US6770651B2 (en) 2004-08-03
DK1401837T3 (da) 2005-11-07
US7238700B2 (en) 2007-07-03
US20030064999A1 (en) 2003-04-03
CA2451244A1 (en) 2003-01-09
KR100883292B1 (ko) 2009-02-11
DE60206756T2 (de) 2006-07-13
WO2003002566A1 (en) 2003-01-09
CA2451244C (en) 2012-01-17

Similar Documents

Publication Publication Date Title
DE60206756D1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
TR200201001T2 (tr) Pürin türevleri
ATE302205T1 (de) Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten
CY1117132T1 (el) Παραγωγο θειαζολιου
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
TR200200161T2 (tr) Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
MXPA04003795A (es) Compuestos de pirimidina y composiciones farmaceuticas que contienen los compuestos.
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
ATE424207T1 (de) Triazoloä4,5-düpyrimidinderivate und ihre verwendung als antagonisten purinerger rezeptoren
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
PE20010430A1 (es) DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a
TNSN07154A1 (en) Purine derivatives for use as adenosin a-2a receptor agonists
ATE254132T1 (de) Antivirale pyrimidin nucleoside derivate
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
LV12712A (lv) Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
BR0008770A (pt) Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica
AR037680A1 (es) Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d
ATE266021T1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
ES2150903T3 (es) Derivados de 2-aralcoxi y 2-alcoxi adenosina de utilidad como vasodilatadores coronarios y como agentes antihipertensivos.
TR200401622T4 (tr) Pürin türevleri
WO2003022219A3 (en) Biarylamino purine antiproliferative agents
ATE407935T1 (de) Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
CY1105879T1 (el) Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
WO2003068776A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401837

Country of ref document: EP